Table 1.
Summary of subunit vaccine development against B. pseudomallei.
References | Subunits | Immunization | Challenge | Percentage survived | ||||
---|---|---|---|---|---|---|---|---|
Dosage and duration | Route | Animal model | Strain | Route | Dosage | |||
Nelson et al. (2004) | Capsular polysaccharide | 3 doses in 28 days | Intraperitoneal | BALB/c | NCTC 4845 | Intraperitoneal | 2 × 105 | 0% at day 28 |
Lipopolysaccharide | 3 doses in 28 days | Intraperitoneal | BALB/c | NCTC 4845 | Intraperitoneal | 2 × 105 | 50% at day 35 | |
Harland et al. (2007) | ATP binding cassette protein, LolC | 3 doses in 28 days | Intraperitoneal | BALB/c | K96243 | Intraperitoneal | 4 × 104 | 80% at day 42 |
Periplasmic binding protein, PotF | 3 doses in 28 days | Intraperitoneal | BALB/c | K96243 | Intraperitoneal | 4 × 104 | 50% at day 42 | |
Oligopeptide binding protein, OppA | 3 doses in 28 days | Intraperitoneal | BALB/c | K96243 | Intraperitoneal | 4 × 104 | 22% at day 42 | |
Legutki et al. (2007) | Peptide mimotopes of exopolysaccharide | 2 doses in 14 days | Intravenous | BALB/c | NCTC 4845 | Intraperitoneal | 4.7 × 104 | 0% at day 30 |
Druar et al. (2008) | BipB, BipC, and BipD proteins | Single dose | Intraperitoneal | BALB/c | Ashdown | Intraperitoneal | 970 | 0% at day 5 |
Hara et al. (2009) | Outer membrane proteins Omp3 and Omp7 | 3 doses in 9 weeks | Intraperitoneal | BALB/c | D286 | Intraperitoneal | 1 × 106 | 50% at day 21 |
Su et al. (2010) | Outer membrane protein Omp85 | 3 doses in 42 days | Intraperitoneal | BALB/c | D286 | Intraperitoneal | 1 × 106 | 70% at day 15 |
Ngugi et al. (2010) | B. thailandensis lipopolysaccharide | 3 doses in 28 days | Intraperitoneal | BALB/c | K96243 | Intraperitoneal | 2 × 104 | 50% at day 35 |
Burtnick et al. (2011) | Integral surface associated component of type VI secretion system, Hcp1 | 3 doses in 14 days | Intraperitoneal | Syrian Hamster | K96243 | Intraperitoneal | 5 × 104 | 50% at day 42 |
Integral surface associated component of type VI secretion system, Hcp2 | 3 doses in 14 days | Intraperitoneal | Syrian Hamster | K96243 | Intraperitoneal | 5 × 104 | 80% at day 42 | |
Integral surface associated component of type VI secretion system, Hcp3 | 3 doses in 14 days | Intraperitoneal | Syrian Hamster | K96243 | Intraperitoneal | 5 × 104 | 50% at day 42 | |
Integral surface associated component of type VI secretion system, Hcp4 | 3 doses in 14 days | Intraperitoneal | Syrian Hamster | K96243 | Intraperitoneal | 5 × 104 | 33% at day 42 | |
Integral surface associated component of type VI secretion system, Hcp5 | 3 doses in 14 days | Intraperitoneal | Syrian Hamster | K96243 | Intraperitoneal | 5 × 104 | 0% at day 42 | |
Integral surface associated component of type VI secretion system, Hcp6 | 3 doses in 14 days | Intraperitoneal | Syrian Hamster | K96243 | Intraperitoneal | 5 × 104 | 50% at day 42 | |
Nieves et al. (2011b) | Outer membrane vesicle | 3 doses in 42 days | Intranasal | BALB/c | 1026b | Aerosol | 1 × 103 | 20% at day 14 |
Subcutaneous | BALB/c | 1026b | Aerosol | 1 × 103 | 60% at day 14 |